Tenex, Intuniv(guanfacine)
Guanfacine, Intuniv (guanfacine) is a small molecule pharmaceutical. Guanfacine was first approved as Tenex on 1986-10-27. It is used to treat attention deficit disorder with hyperactivity and hypertension in the USA. It has been approved in Europe to treat attention deficit disorder with hyperactivity.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
| mental disorders | D001523 |
Trade Name
FDA
EMA
Guanfacine, Intuniv (discontinued: Guanfacine, Tenex)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| guanfacine | ANDA | 2024-10-04 |
| guanfacine er | ANDA | 2023-05-04 |
| guanfacine extended-release | ANDA | 2024-10-04 |
| guanfacine hydrochloride | ANDA | 2024-10-28 |
| intuniv | New Drug Application | 2022-12-23 |
| tenex | New Drug Application | 2013-05-08 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hypertension | EFO_0000537 | D006973 | I10 |
| attention deficit disorder with hyperactivity | EFO_0003888 | D001289 | F90 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
94 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | 1 | 2 | 8 | 12 | 8 | 31 |
| Hyperkinesis | D006948 | HP_0000752 | — | — | 3 | 7 | 9 | 5 | 24 |
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | — | 2 | 1 | 3 | 7 |
| Syndrome | D013577 | — | — | — | 1 | 1 | 2 | 2 | 6 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | 1 | — | 1 | 1 | 3 |
| Aggression | D000374 | EFO_0003015 | — | — | — | — | 3 | — | 3 |
| Personality disorders | D010554 | HP_0012075 | F60.6 | — | 1 | — | 1 | 1 | 3 |
| Autism spectrum disorder | D000067877 | HP_0000729 | F84.0 | — | — | — | 2 | 1 | 3 |
| Pervasive child development disorders | D002659 | EFO_0003756 | F84 | — | — | — | 2 | 1 | 3 |
| Sleep initiation and maintenance disorders | D007319 | — | F51.01 | — | — | — | 1 | 1 | 2 |
Show 39 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Critical illness | D016638 | — | — | — | 1 | 1 | — | — | 2 |
| Delirium | D003693 | — | R41.0 | — | 1 | 1 | — | — | 2 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alcoholism | D000437 | EFO_0003829 | F10.1 | 3 | 3 | — | — | — | 5 |
| Alcohol drinking | D000428 | EFO_0004329 | — | 2 | 4 | — | — | — | 5 |
| Marijuana abuse | D002189 | EFO_0007191 | F12 | 1 | 2 | — | — | — | 3 |
| Down syndrome | D004314 | EFO_0001064 | Q90 | — | 1 | — | — | 1 | 2 |
| Smoking cessation | D016540 | EFO_0004319 | — | — | 2 | — | — | — | 2 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | 1 | — | — | — | 2 |
| Recurrence | D012008 | — | — | 2 | 1 | — | — | — | 2 |
| Smoking | D012907 | EFO_0004318 | — | — | 2 | — | — | — | 2 |
| Cocaine-related disorders | D019970 | — | F14 | 1 | 1 | — | — | — | 2 |
| Neuralgia | D009437 | EFO_0009430 | — | — | 1 | — | — | — | 1 |
Show 12 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
| Pure autonomic failure | D054970 | — | — | 1 | — | — | — | — | 1 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | 1 | — | — | — | — | 1 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | 1 | — | — | — | — | 1 |
| Mindfulness | D064866 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bursitis | D002062 | EFO_1000941 | M71.9 | — | — | — | — | 3 | 3 |
| Covid-19 | D000086382 | — | — | — | — | — | — | 2 | 2 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 1 | 1 |
| Heart failure | D006333 | HP_0001635 | I50 | — | — | — | — | 1 | 1 |
| Infections | D007239 | EFO_0000544 | — | — | — | — | — | 1 | 1 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | — | — | — | 1 | 1 |
| Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | — | — | — | 1 | 1 |
| Hemophilia a | D006467 | EFO_0007267 | D66 | — | — | — | — | 1 | 1 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 1 | 1 |
| Pneumonia | D011014 | EFO_0003106 | — | — | — | — | — | 1 | 1 |
Show 26 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Guanfacine |
| INN | guanfacine |
| Description | Guanfacine is a member of acetamides. |
| Classification | Small molecule |
| Drug class | antihypertensives (guanidine deriviatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N=C(N)NC(=O)Cc1c(Cl)cccc1Cl |
Identifiers
| PDB | — |
| CAS-ID | 29110-47-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL862 |
| ChEBI ID | 5558 |
| PubChem CID | 3519 |
| DrugBank | DB01018 |
| UNII ID | 30OMY4G3MK (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Estimated US medical usage
Guanfacine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,308 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,798 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use